---
title: "Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290552106.md"
description: "Armata Pharmaceuticals received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense for its AP-SA02 program, bringing total DoD support to $28.7 million. The funds aim to prepare the drug for Phase 3 trials targeting complicated Staphylococcus aureus bacteremia. Armata plans to start a Phase 3 superiority study in the second half of 2026."
datetime: "2026-06-23T11:01:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290552106.md)
  - [en](https://longbridge.com/en/news/290552106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290552106.md)
---

# Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program

-   Armata Pharmaceuticals received USD 2.5 million in additional non-dilutive U.S. Department of Defense funding for AP-SA02. \* Total DoD support for the program reached USD 28.7 million; funds target Phase 3 readiness in complicated Staphylococcus aureus bacteremia. \* Award flows through the Medical Technology Enterprise Consortium; program managed by the Naval Medical Research Command. \* Armata targets a Phase 3 superiority study start in 2H 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606230700PR\_NEWS\_USPR\_\_\_\_\_LA89675) on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARMP.US](https://longbridge.com/en/quote/ARMP.US.md)

## Related News & Research

- [Armata Advances AP-SA02 Toward Phase 3 Trial Launch](https://longbridge.com/en/news/293209036.md)
- [Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment](https://longbridge.com/en/news/293234406.md)
- [Arm’s Biggest Opportunity Comes With Its Biggest Risk](https://longbridge.com/en/news/294403886.md)
- [Dear Arm Stock Fans, Mark Your Calendars for July 29](https://longbridge.com/en/news/294092734.md)
- [Arm posts shareholder letter for fiscal Q1 2027 results on investor relations website](https://longbridge.com/en/news/294253854.md)